DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

Morgan Stanley Maintains Overweight on Epizyme, Raises Price Target to $28

Morgan Stanley maintains Epizyme (NASDAQ:EPZM) with a Overweight and raises the price target from $26 to $28.

Benzinga · 01/24/2020 14:28

Morgan Stanley maintains Epizyme (NASDAQ:EPZM) with a Overweight and raises the price target from $26 to $28.